PharmaHemp d.o.o. hereby declares that it is bound to impartiality and that it prevents potential commercial, financial and other strains on the operations of the organizational unit Analytical laboratories. Through independent and impartial operations, we ensure equal treatment of clients and fair and professional assessments in organizational unit Analytical laboratories.

Impartiality is managed according to the quality management system and the systematic process of risk management, where we ensure continual identification and prevention of potential risks. With applicable procedures, we manage all potential internal and external factors which could affect the impartiality of the organizational unit Analytical laboratories.

The process of risk management encompasses the preparation of a risk assessment where we analyse, assess, control and monitor the identified risks. If the risk exceeds the acceptable limits, we immediately perform risk mitigation or elimination measures. We have performed a detailed risk assessment and reviewed and analysed various relationships that could impair the impartiality of the operation in organizational unit Analytical laboratories: the relationship with the parent organization, the relationships with the departments within the organization, related companies, regulators, staff, clients and external providers.

The impact of the company’s ownership and organizational structure on the testing results and impartiality is small, have adopted some measures for the elimination of potential employee impact and have excluded any potential influence of people or organizations outside of the organizational unit Analytical laboratories.

The organizational unit Analytical laboratories also does not perform any activities that could endanger the trust in the independence of its assessment or the integrity of its testing activities. The quality and impartiality policy is additionally ensured with regular calibration, qualification and validation of equipment, rooms and processes, with interlaboratory comparisons and employee training. If new risks for the impartiality of laboratory operations are discovered, we perform a new risk assessment which we review and complement, if necessary, at the annual management review.

Andrej Sušnik

Chief Executive Officer

dr. Boštjan Jančar

Chief Laboratory Officer CDO/LAB

Janja Ahej

Analytical Laboratory Manager MAN/LAB

Accepted in the document: VOD-GEN-011 – Nepristranskost-02

Date of signature of a valid statement of impartiality: 1.12.2022

Date of publication: 2.12.2022